Literature DB >> 25224646

The absolute lymphocyte to monocyte ratio is associated with poor prognosis in classical Hodgkin lymphoma patients younger than 60 years of age.

Young Wha Koh1, Se Jin Jung2, Dok Hyun Yoon3, Cheolwon Suh3, Hee Jeong Cha2, Heounjeong Go4, Ji Eun Kim5, Chul-Woo Kim5, Jooryung Huh4.   

Abstract

Recent studies suggest that absolute lymphocyte count, absolute monocyte count and their ratio [lymphocyte/monocyte ratio (LMR)] at diagnosis may predict survival in classical Hodgkin lymphoma (cHL). Here, we investigated the prognostic significance of LMR in cHL patients in relation to age of patients. Subjects included 351 cHL patients (age range from 4 to 84 years, median age 34 years, sex ratio 1.58) who had been followed-up for a median period of 59 months (range, 0.1-245 months). The estimated 5-year overall survival (OS) rate was 86.8%. Subgroup analysis was performed according to patients' age; non-elderly group (<60 years of age) versus elderly group (≥60 years of age). There was no significant difference in the level of absolute lymphocyte count, absolute monocyte count or LMR between the age groups. Using receiver operating characteristic curve analysis, the optimal cut-off value of LMR for the entire cohort was determined at 2.8, whereas the optimal cut-off for the elderly group was 2.2. In the non-elderly group (<60 years old), patients with LMR <2.8 had significantly lower OS or lymphoma-specific survival compared with those with LMR ≥2.8 (p < 0.001, both). In contrast, neither the LMR value of 2.8 or 2.2 predicted survival in the elderly group. In multivariate analysis, LMR remained a significant prognostic factor for OS (p = 0.049). The results of our analysis suggest that low LMR is associated with poor OS in patients of <60 years old.
Copyright © 2014 John Wiley & Sons, Ltd.

Entities:  

Keywords:  Hodgkin lymphoma; age; lymphocyte/monocyte ratio; lymphocytes; monocytes

Mesh:

Year:  2014        PMID: 25224646     DOI: 10.1002/hon.2155

Source DB:  PubMed          Journal:  Hematol Oncol        ISSN: 0278-0232            Impact factor:   5.271


  10 in total

1.  Prognostic Implication of the Absolute Lymphocyte to Absolute Monocyte Count Ratio in Patients With Classical Hodgkin Lymphoma Treated With Doxorubicin, Bleomycin, Vinblastine, and Dacarbazine or Equivalent Regimens.

Authors:  Theodoros P Vassilakopoulos; Maria N Dimopoulou; Maria K Angelopoulou; Kyriaki Petevi; Gerassimos A Pangalis; Maria Moschogiannis; Maria Dimou; George Boutsikas; Alexandros Kanellopoulos; Gabriella Gainaru; Eleni Plata; Pagona Flevari; Katerina Koutsi; Loula Papageorgiou; Vassilios Telonis; Panayiotis Tsaftaridis; Sotirios Sachanas; Xanthoula Yiakoumis; Pantelis Tsirkinidis; Nora-Athina Viniou; Marina P Siakantaris; Eleni Variami; Marie-Christine Kyrtsonis; John Meletis; Panayiotis Panayiotidis; Kostas Konstantopoulos
Journal:  Oncologist       Date:  2016-02-26

2.  Prognostic value of peripheral blood lymphocyte-to-monocyte ratio in patients with solid tumors: a meta-analysis.

Authors:  Jun-Jie Teng; Jian Zhang; Tian-Yi Zhang; Shu Zhang; Bao-Sheng Li
Journal:  Onco Targets Ther       Date:  2015-12-21       Impact factor: 4.147

3.  Positive effect of HPV status on prognostic value of blood lymphocyte-to-monocyte ratio in advanced cervical carcinoma.

Authors:  Si-Wei Li; Wenxin Yuan; Bo Zhao; Zhuo-Kai He; Xiang Guo; Wei-Xiong Xia; Li-Hua Xu
Journal:  Cancer Cell Int       Date:  2016-07-04       Impact factor: 5.722

Review 4.  Prognostic role of lymphocyte to monocyte ratio for patients with cancer: evidence from a systematic review and meta-analysis.

Authors:  Liangyou Gu; Hongzhao Li; Luyao Chen; Xin Ma; Xintao Li; Yu Gao; Yu Zhang; Yongpeng Xie; Xu Zhang
Journal:  Oncotarget       Date:  2016-05-31

5.  Absolute monocyte count at diagnosis could improve the prognostic role of early FDG-PET in classical Hodgkin lymphoma patients.

Authors:  Alessia Bari; Luigi Marcheselli; Raffaella Marcheselli; Samantha Pozzi; Maria Christina Cox; Cinzia Baldessari; Paola Ferri; Paolo Gobbi; Luca Baldini; Tamar Tadmor; Pellegrino Musto; Massimo Federico; Stefano Sacchi
Journal:  Br J Haematol       Date:  2016-10-26       Impact factor: 6.998

6.  [The correlations and prognostic value of neutrophil to lymphocyte ratio, immunophenotype and cytogenetic abnormalities in patients with newly diagnosed multiple myeloma].

Authors:  J J Hu; S M Nie; Y Gao; X S Yan; J X Huang; T L Li; S S Liu; C X Mao; J J Zhou; Y J Xu; W Wang; F J Meng; X Q Feng
Journal:  Zhonghua Xue Ye Xue Za Zhi       Date:  2019-12-14

7.  Prognostic Significance of the Preoperative Lymphocyte to Monocyte Ratio in Patients with Gallbladder Carcinoma.

Authors:  Weiyu Xu; Xiaoqian Wu; Xuezhu Wang; Si Yu; Gang Xu; Jianping Xiong; Junwei Zhang; Xinting Sang; Yongchang Zheng; Wei Liu
Journal:  Cancer Manag Res       Date:  2020-05-11       Impact factor: 3.989

8.  The Prognostic Value of Blood-Based Biomarkers in Patients With Testicular Diffuse Large B-Cell Lymphoma.

Authors:  Jing Yang; Xinli Guo; Jianqi Hao; Yiting Dong; Tao Zhang; Xuelei Ma
Journal:  Front Oncol       Date:  2019-12-10       Impact factor: 6.244

9.  A Correlation Between Monocyte to Lymphocyte Ratio and Long-Term Prognosis in Patients With Coronary Artery Disease After PCI.

Authors:  Feng-Hua Song; Ying-Ying Zheng; Jun-Nan Tang; Wei Wang; Qian-Qian Guo; Jian-Chao Zhang; Yan Bai; Kai Wang; Meng-Die Cheng; Li-Zhu Jiang; Ru-Jie Zheng; Lei Fan; Zhi-Yu Liu; Xin-Ya Dai; Zeng-Lei Zhang; Xiao-Ting Yue; Jin-Ying Zhang
Journal:  Clin Appl Thromb Hemost       Date:  2021 Jan-Dec       Impact factor: 2.389

10.  The neutrophil to lymphocyte ratio (NLR) and the presence of large nodal mass are independent predictors of early response: A subanalysis of the prospective phase II PET-2-adapted HD0607 trial.

Authors:  Alessandra Romano; Chiara Pavoni; Francesco Di Raimondo; Corrado Tarella; Simonetta Viviani; Andrea Rossi; Caterina Patti; Marco Picardi; Maria Cantonetti; Giorgio La Nasa; Livio Trentin; Silvia Bolis; Valerio Zoli; Paolo Gavarotti; Paolo Corradini; Michele Cimminiello; Corrado Schiavotto; Guido Parvis; Roberta Zanotti; Guido Gini; Andrés J M Ferreri; Piera Viero; Stephane Chauvie; Alberto Biggi; Alessandro Massimo Gianni; Andrea Gallamini; Alessandro Rambaldi
Journal:  Cancer Med       Date:  2020-11-06       Impact factor: 4.452

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.